| NKCx - Women with negative cell samples 0.5-3.5 yrs before CIN3/AIS |
| and 3.5-10.5 yrs before Invasive cancer |
| Diagnose CIN3/AIS 2017 | Diagnose Invasive cancer 2017 | |||||||
|---|---|---|---|---|---|---|---|---|
| Lab | Frequency diagnosed women |
Frequency women with cell samples |
Proportion with cell samples |
Frequency cell samples mean |
Frequency diagnosed women |
Frequency women with cell samples |
Proportion with cell samples |
Frequency cell samples mean |
| 051 S:t Göran | 939 | 385 | 41.0% | 1.1 | 29 | 17 | 58.6% | 1.9 |
| 088 (081) Huddinge | 894 | 306 | 34.2% | 1.2 | 103 | 55 | 53.4% | 1.8 |
| 121 Uppsala | 308 | 84 | 27.3% | 1.1 | 29 | 15 | 51.7% | 1.8 |
| 131 Eskilstuna | 141 | 42 | 29.8% | 1.3 | 18 | 8 | 44.4% | 1.3 |
| 211 Linköping | 543 | 181 | 33.3% | 1.2 | 55 | 28 | 50.9% | 1.9 |
| 231 Jönköping | 331 | 92 | 27.8% | 1.2 | 23 | 11 | 47.8% | 1.8 |
| 241 Växjö | 127 | 21 | 16.5% | 1.3 | 8 | 4 | 50.0% | 1.8 |
| 251 Kalmar | 395 | 101 | 25.6% | 1.2 | 16 | 9 | 56.3% | 1.7 |
| 271 Karlskrona | 129 | 42 | 32.6% | 1.2 | 9 | 4 | 44.4% | 2.0 |
| 281 Kristianstad | 188 | 62 | 33.0% | 1.2 | 11 | 6 | 54.5% | 1.2 |
| 301 Malmö | 286 | 75 | 26.2% | 1.2 | 12 | 6 | 50.0% | 2.0 |
| 411 Lund | 333 | 93 | 27.9% | 1.1 | 18 | 8 | 44.4% | 2.0 |
| 421 Halmstad | 275 | 97 | 35.3% | 1.1 | 17 | 9 | 52.9% | 1.9 |
| 431 Helsingborg | 355 | 106 | 29.9% | 1.5 | 20 | 7 | 35.0% | 2.1 |
| 501 Göteborg | 953 | 262 | 27.5% | 1.2 | 51 | 34 | 66.7% | 2.0 |
| 511 Trollhättan | 174 | 39 | 22.4% | 1.1 | 15 | 6 | 40.0% | 2.3 |
| 521 Borås | 273 | 76 | 27.8% | 1.2 | 16 | 6 | 37.5% | 1.3 |
| 531 Skövde | 609 | 175 | 28.7% | 1.2 | 28 | 16 | 57.1% | 1.6 |
| 541 Karlstad | 500 | 195 | 39.0% | 1.2 | 19 | 13 | 68.4% | 1.8 |
| 551 Örebro | 314 | 88 | 28.0% | 1.0 | 15 | 7 | 46.7% | 1.9 |
| 561 Västerås | 326 | 126 | 38.7% | 1.1 | 17 | 8 | 47.1% | 1.6 |
| 571 Dalarna | 381 | 140 | 36.7% | 1.2 | 16 | 10 | 62.5% | 2.0 |
| 611 Gävle | 207 | 90 | 43.5% | 1.1 | 22 | 9 | 40.9% | 1.9 |
| 621 Sundsvall | 268 | 61 | 22.8% | 1.2 | 11 | 4 | 36.4% | 1.5 |
| 631 Jämtland | 207 | 55 | 26.6% | 1.2 | 8 | 6 | 75.0% | 1.5 |
| 641 Umeå | 379 | 81 | 21.4% | 1.2 | 18 | 9 | 50.0% | 1.9 |
| 651 Sunderby | 331 | 111 | 33.5% | 1.1 | 15 | 9 | 60.0% | 1.7 |
| 851 Medilab | 684 | 231 | 33.8% | 1.1 | 17 | 8 | 47.1% | 1.5 |
| Total | 10850 | 3417 | 31.5% | 1.2 | 636 | 332 | 52.2% | 1.8 |
| NOTE: Restricted to histopathological outcome year 2017 from cervix (T83). |
| This is information for laboratory quality assurance (audit), which seeks out and after reviewing the previous cytological samples from women who later received a dysplasia or cancer. The screening is based on repetitive samples within the given range. The percentages indicate how many cases of dysplasia or cancer 'missed' by screening, but the proportion of women with dysplasia or cancer some time during the last screening interval had a Pap smear that could be included in an audit. |
| Updated 24AUG2018 13:54:35 |